Scilex Holding (SCLX)
Bid | 0.27 |
Market Cap | 67.5M |
Revenue (ttm) | 105.69M |
Net Income (ttm) | -168.16M |
EPS (ttm) | -0.81 |
PE Ratio (ttm) | -0.34 |
Forward PE | -1.48 |
Analyst | Buy |
Ask | 0.29 |
Volume | 926,317 |
Avg. Volume (20D) | 1,432,800 |
Open | 0.28 |
Previous Close | 0.28 |
Day's Range | 0.26 - 0.29 |
52-Week Range | 0.21 - 2.30 |
Beta | 1.16 |
About SCLX
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural i...
Analyst Forecast
According to 4 analyst ratings, the average rating for SCLX stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 4766.62% from the latest price.
Stock Forecasts
10 months ago · https://www.defenseworld.net
Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial ComparisonSorrento Therapeutics (OTCMKTS:SRNEQ – Get Free Report) and bluebird bio (NASDAQ:BLUE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compar...